Meeting News

SCORE2 subanalysis: Visual gains made after treatment switch

Michael Ip
Michael S. Ip

WAIKOLOA, Hawaii — Visual acuity letter score and central subfield thickness both improved in eyes treated with aflibercept after a poor response to bevacizumab, Michael S. Ip, MD, told colleagues at Retina 2019.

In a secondary analysis of the SCORE2 trial, poor responders at month 6 were switched from either aflibercept or bevacizumab to a different regimen to determine whether the switch would improve visual acuity or central subfield thickness at month 12.

“Notably, none of these eyes that have been deemed poor responders at month 6 ever catch up to those eyes that were deemed good responders at month 6,” Ip said.

Fourteen participants failed on aflibercept treatment and were switched to treatment to dexamethasone; 35 participants failed on bevacizumab treatment and were switched to aflibercept.

In the eyes switched to dexamethasone, at month 12 the mean change in visual acuity letter score was 2.63 and mean change in central subfield thickness was 46 μm. In eyes switched to aflibercept, the mean change in visual acuity letter score and central subfield thickness were both statistically significantly different, estimated to be 10.27 and –125.4 μm at month 12 (both P < .001).

The subanalysis is essentially a switching study without a control group, Ip said. “That is one of the criticisms of this particular analysis.” – by Patricia Nale, ELS

 

References:

Ip M. Management of central retinal vein occlusion: A review and update from the SCORE2 study. Presented at: Retina 2019; Jan. 20-25, 2019; Waikoloa, Hawaii.

Ip MS, et al. JAMA Ophthalmol. 2019;doi: 0.1001/jamaophthalmol.2018.6111.

Disclosure: Ip reports he is a consultant to Boehringer Ingelheim, Oxurion (ThromboGenics), Quark, Omeros, Genentech, Astellas and Allergan.

Michael Ip
Michael S. Ip

WAIKOLOA, Hawaii — Visual acuity letter score and central subfield thickness both improved in eyes treated with aflibercept after a poor response to bevacizumab, Michael S. Ip, MD, told colleagues at Retina 2019.

In a secondary analysis of the SCORE2 trial, poor responders at month 6 were switched from either aflibercept or bevacizumab to a different regimen to determine whether the switch would improve visual acuity or central subfield thickness at month 12.

“Notably, none of these eyes that have been deemed poor responders at month 6 ever catch up to those eyes that were deemed good responders at month 6,” Ip said.

Fourteen participants failed on aflibercept treatment and were switched to treatment to dexamethasone; 35 participants failed on bevacizumab treatment and were switched to aflibercept.

In the eyes switched to dexamethasone, at month 12 the mean change in visual acuity letter score was 2.63 and mean change in central subfield thickness was 46 μm. In eyes switched to aflibercept, the mean change in visual acuity letter score and central subfield thickness were both statistically significantly different, estimated to be 10.27 and –125.4 μm at month 12 (both P < .001).

The subanalysis is essentially a switching study without a control group, Ip said. “That is one of the criticisms of this particular analysis.” – by Patricia Nale, ELS

 

References:

Ip M. Management of central retinal vein occlusion: A review and update from the SCORE2 study. Presented at: Retina 2019; Jan. 20-25, 2019; Waikoloa, Hawaii.

Ip MS, et al. JAMA Ophthalmol. 2019;doi: 0.1001/jamaophthalmol.2018.6111.

Disclosure: Ip reports he is a consultant to Boehringer Ingelheim, Oxurion (ThromboGenics), Quark, Omeros, Genentech, Astellas and Allergan.

    See more from Hawaiian Eye/Retina Meeting